Skip to content
Evigrade
CriticalAntidepressant, norepinephrine-dopamine reuptake inhibitor (NDRI); a separate formulation (Zyntabac) is licensed for smoking cessation×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative

Updated · Methodology

Mechanism

Bupropion inhibits the reuptake of dopamine and norepinephrine (bupropion label, US Food and Drug Administration, FDA). Tranylcypromine is an irreversible, non-selective inhibitor of monoamine oxidase (MAO) A and B, the enzyme that breaks down serotonin, norepinephrine and dopamine (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Both drugs strengthen catecholamine signalling by different mechanisms, and together they make adverse reactions more likely (bupropion SmPC, AEMPS), above all hypertensive reactions (bupropion FDA label). In animal studies, the MAO inhibitor phenelzine increased the acute toxicity of bupropion (bupropion FDA label). Tranylcypromine and its metabolites leave the body within 24 hours, but full MAO activity returns only 3–5 days after the last dose (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine FDA label).

Symptoms

With monoamine oxidase (MAO) inhibitors, bupropion carries a higher risk of hypertensive reactions (bupropion label, US Food and Drug Administration, FDA). Tranylcypromine may intensify bupropion-induced seizures and agitation (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US tranylcypromine label names serotonin syndrome as the main risk with all antidepressants, bupropion included (tranylcypromine FDA label). A hypertensive crisis during tranylcypromine treatment may come with a fast heart rate, facial flushing, headache (especially at the back of the head), neck stiffness, nausea, vomiting and sensitivity to light. In isolated cases, particularly with a drug interaction, the crisis can lead to intracranial haemorrhage (tranylcypromine SmPC, AEMPS). In a hypertensive emergency, blood pressure is severely raised (for example, above 180/120 mm Hg) and there are signs of organ damage. Sweating, dilated pupils, shortness of breath, confusion, constricting chest pain and seizures may occur (tranylcypromine FDA label).

Management

The combination is contraindicated. The bupropion summaries of product characteristics (SmPCs), both for depression and for smoking cessation, contraindicate all monoamine oxidase inhibitors (MAOIs). Tranylcypromine is an irreversible, non-selective MAOI according to its own SmPC (bupropion and tranylcypromine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US labels list bupropion among the drugs contraindicated with tranylcypromine and contraindicate MAOIs intended to treat psychiatric disorders with bupropion (tranylcypromine and bupropion labels, US Food and Drug Administration, FDA). The Spanish tranylcypromine SmPC is less strict: it places bupropion among combinations to avoid rather than among contraindications, because bupropion-induced seizures and agitation may intensify with tranylcypromine (tranylcypromine SmPC, AEMPS). Start bupropion at least 14 days after stopping tranylcypromine (bupropion and tranylcypromine SmPCs, AEMPS; bupropion FDA label). The 24-hour interval in the bupropion SmPC applies only to reversible MAOIs. When switching from bupropion to tranylcypromine, the Spanish tranylcypromine SmPC recommends a drug-free interval of about 5 half-lives of bupropion and its active metabolites (tranylcypromine SmPC, AEMPS). The US tranylcypromine label recommends 4–5 half-lives (tranylcypromine FDA label), and the US bupropion label at least 14 days (bupropion FDA label). Measure blood pressure before starting tranylcypromine and monitor it closely during treatment (tranylcypromine FDA label). If the drugs have nevertheless been taken together and palpitations, headache or other early signs of a hypertensive crisis appear, interrupt treatment and assess the patient at once. Stop tranylcypromine and any other drug that may have caused the crisis at once. If blood pressure is severely raised (for example, above 180/120 mm Hg) and there are signs of organ damage, lower it immediately (tranylcypromine FDA label). If seizures occur during bupropion treatment, stop bupropion and do not restart it (bupropion SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Bupropion

Other interactions with Tranylcypromine